Rarely do I see such flawed analysis in an abstract that it makes me read the full article.
irAEs Can Predict PFS and OS In Patients w/ Metastatic Renal Cell Carcinoma Treated w/ Immune Checkpoint Inhibitors - PubMed (nih.gov)
English
Chung-Han Lee 李宗翰, MD/PhD
212 posts
Chung-Han Lee 李宗翰, MD/PhD
@ChungHanLee3
Physician-Scientist Focused on Biomarker Development and Novel Therapies
New York, NY Katılım Mart 2019
264 Takip Edilen685 Takipçiler
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Very excited to share with you incredibly promising data for #zanzalintinib (#XL092) in patients with #kidneycancer. A million thanks to @kidneycancer for allowing us to present this data in a highlighted oral session at #IKCSNA23! See my slides/thoughts here: (1/9)
English
Great to see everyone at ESMO. @KidneyCancer keep up the good work. Our patients need you.
Kidney Cancer@KidneyCancer
Enjoyed meeting old friends at #ESMO23, making new connections, seeing practice-changing research, and having lots of great discussions about how to advance #kidneycancer science by and for patients 🤝 see you next year @myESMO!
English
Ending my last clinic @MSKCancerCenter with dinner with @IyerGopa and @KotechaMD. So grateful to work 12 years with the best mentor I have ever had, @motzermd. So proud of @KellyNFitz who is starting @UCSF . Excited to start a new chapter of my career on 8/14.
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
The association between FGFR3 alterations and response to platinum-based chemotherapy in locally advanced and metastatic #UrothelialCarcinoma. @IyerGopa @MSKCancerCenter joins @UroCancerMD @VUMCurology in this discussion on UroToday > bit.ly/41G3smP @EUplatinum
English
So lucky to have had the chance to work with @KellyNFitz. UCSF is so lucky to have you. We are all expecting great things from you.
Kelly Fitzgerald@KellyNFitz
A life/career update, delayed by a transcontinental move: last month I graduated @MSKCancerCenter fellowship, and this week I joined the GU Med Onc faculty group at @UCSFCancer! Owe so much to my mentors @ChungHanLee3 @motzermd and many others, and so excited for what’s to come.
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
A life/career update, delayed by a transcontinental move: last month I graduated @MSKCancerCenter fellowship, and this week I joined the GU Med Onc faculty group at @UCSFCancer! Owe so much to my mentors @ChungHanLee3 @motzermd and many others, and so excited for what’s to come.
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
🎥@ChungHanLee3 of @MSKCancerCenter discusses combining lenvatinib and pembrolizumab as a first-line treatment for non-clear cell RCC, aiming to provide a new treatment option for this subgroup:
➡️ow.ly/Izvu50Pv0UX⬅️
#ASCO23 #KCSM #UroOnc #UroSoMe #ImmunoOnc
English
RT @BrendanGuercio: Thank u @NicoleKuderer! So appreciative of @BladderCancerUS, who supported work with @IyerGopa @ChungHanLee3 showing as…
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Thanks @SWOG for highlighting #PAPMET2 as the trial of the week. Prior IO trials suggest it is time for a randomized trial. Many have contributed to our understanding of this disease--lets keep moving forward! @AlbigesL @ChungHanLee3 @montypal swog.org/clinical-trial…
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
#KEYNOTEB61 study reveals promising results of lenvatinib + pembrolizumab combo in non-clear cell #RCC. @ChungHanLee3 @MSKCancerCenter joins @PBarataMD @caseccc to discuss his significant contributions to #KidneyCancer research. #WatchNow > bit.ly/3Q6JH5f
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Longer follow-up data from the Study 111/KN146 showed that lenvatinib and pembrolizumab produced durable responses lasting at least 18 months in many patients with metastatic RCC. @ChungHanLee3 @MSKCancerCenter @KidneyCancer #KCRS23 #kcsm ow.ly/f5Tp50PfvZ6
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic RCC, including in subsets of patients who had received or were naïve to checkpoint inhibitors. @ChungHanLee3 @MSKCancerCenter @KidneyCancer #KCRS23 #kcsm ow.ly/VAZR50PfvWF
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
“The responses remained durable in a subset of patients who were previously treated but ICI naïve, but also in patients who received ICIs as prior systemic therapy,” said Chung-Han Lee, MD, PhD. #kicsm | @kidneycan @ChungHanLee3
ow.ly/C1Zv50PfBsg
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCancerCenter @kidneycan #KCRS23 #kcsm ow.ly/Vup250Pc5I3
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23
full text: authors.elsevier.com/a/1hP1c5EIIgLp…
Thanks to all who change
rareRCC pts Tx!
Paris, France 🇫🇷 English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Special thanks to our superstar #IKCSNA23 planning committee!
@drphil_urology @TiansterZhang @bergsa83 #MariaCarlo #DanGeynisman @ChungHanLee3 #JodieMaranchie @spsutkaMD #KiranVirdee @ZakhariaYousef kidneycancer.org/ikcs/2023-ikcs…
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
Pembrolizumab plus lenvatinib yielded anti-tumor activity and a manageable safety profile as a first-line treatment option for patients with advanced non–clear cell renal cell carcinoma regardless of histology. #kicsm #ASCO23 | @ASCO @ChungHanLee3
ow.ly/8yIL50OPUH4
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
@kidneycancer brings together the #kidneycancer community for research & practice updates twice yearly #IKCS symposia. I have had the privilege to help plan over the years w/ @eric_facs @ChungHanLee3 @BradMcG04 @bergsa83 et al. Save the date for Nov 10-11, 2023 in Nashville!
English
Chung-Han Lee 李宗翰, MD/PhD retweetledi
#ASCO2023 Interesting work by @BrendanGuercio, @ChungHanLee3, and colleagues from @MSKCancerCenter showing an association between high fiber intake and prolonged PFS in urothelial and renal cell carcinoma. Validation is warranted. Abstract 4598.
English